throbber
Case IPR2016-00318
`Patent 7,772,209
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`
`SANDOZ INC.,
`APOTEX INC., APOTEX CORP.,
`EMCURE PHARMACEUTICALS LTD.,
`HERITAGE PHARMA LABS INC.,
`HERITAGE PHARMACEUTICALS INC.,
`GLENMARK PHARMACEUTICALS, INC., USA,
`GLENMARK HOLDING SA,
`GLENMARK PHARMACEUTICALS, LTD.,
`MYLAN LABORATORIES LIMITED,
`TEVA PHARMACEUTICALS USA, INC.
`and FRESENIUS KABI USA, LLC,
`
`Petitioners
`
`v .
`ELI LILLY AND COMPANY,
`Patent Owner.
`
`Case IPR2016-003181
`U.S. Patent 7,772,209
`
`
`
`
`
`
`
`
`PETITIONER’S UPDATED EXHIBIT LIST
`
`
`1 Cases IPR2016-01340 and IPR2016-01429 have been joined with the instant
`
`proceeding.
`
`

`
`Case IPR2016-00318
`Patent 7,772,209
`Filing Date
`
`Description
`
`U.S. Patent No. 7,772,209
`
`File History of U.S. Patent Application
`No. 11/776,329, which issued as U.S. Patent No.
`7,772,209 on August 10, 2010
`
`Findings Of Fact And Conclusions Of Law
`Following Bench Trial August 19, 2013, in Eli
`Lilly & Co. v. Teva Parenteral Medicines, Inc.,
`Case No. 1:10-cv-1376, Dkt. 336 (S.D. Ind.
`March 31, 2014)
`
`12/14/2015
`
`12/14/2015
`
`12/14/2015
`
`12/14/2015
`
`12/14/2015
`
`12/14/2015
`
`12/14/2015
`
`12/14/2015
`
`Exhibit
`No.
`
`Exhibit
`1001:
`
`Exhibit
`1002:
`
`Exhibit
`1003:
`
`Exhibit
`1004:
`
`Exhibit
`1005:
`
`Exhibit
`1006:
`
`Declaration of Ron D. Schiff, M.D., Ph.D.
`
`12/14/2015
`
`U.S. Patent No. 5,217,974
`
`C. Niyikiza, et al., MTA (LY231514): Relationship
`of vitamin metabolite profile, drug exposure, and
`other patient characteristics to toxicity, Annals
`Oncology 9 (Suppl. 4): 125-140, Abstract 609P,
`(1998)
`
`Exhibit
`1007:
`
`Hilary Calvert, An Overview of Folate
`Metabolism: Features Relevant to the Action and
`Toxicities of Antifolate Anticancer Agents,
`Seminars Oncology, 26: 3-10 (1999)
`
`Exhibit
`1008:
`
`Textbook of Small Animal Medicine (John K. Dunn
`ed. 1999)
`
`Exhibit
`1009:
`
`Sidney Farber, et al., Temporary Remissions in
`acute leukemia in children produced by folic acid
`antagonist, 4-aminopteroylglutamic acid
`(aminopterin), New Eng. J. Med., 238(23): 787-793
`
`
`
`2
`
`

`
`Exhibit
`No.
`
`Exhibit
`1010:
`
`Exhibit
`1011:
`
`Exhibit
`1012:
`
`Exhibit
`1013
`
`Exhibit
`1014
`
`Description
`
`Case IPR2016-00318
`Patent 7,772,209
`Filing Date
`
`Sarah L. Morgan, et al., Supplementation with Folic
`Acid during Methotrexate Therapy for Rheumatoid
`Arthritis, Annals Internal Med., 121: 833-841 (1994)
`
`12/14/2015
`
`G.B. Grindey, et al., Reversal of the toxicity but not
`the antitumor activity of Lometrexol by folic acid,
`Am. Ass’n Cancer Res., 32: 324, Abstract 1921
`(1991)
`
`Laurane G. Mendelsohn, et al., Preclinical and
`Clinical Evaluation of the Glycinamide
`Ribonucleotide Formyltransferase Inhibitors
`Lometrexol and LY309887, in Anticancer Drug Dev.
`Guide: Antifolate Drugs Cancer Therapy, (Ann L.
`Jackman, ed.) Ch. 12: 261-80 (1999)
`
`12/14/2015
`
`12/14/2015
`
`John F. Worzalla, et al., Role of Folic Acid in
`Modulating the Toxicity and Efficacy of the
`Multitargeted Antifolate, LY231514, Anticancer Res.,
`18: 3235-3240 (1998)
`
`12/14/2015
`
`L. Hammond, et al., A Phase I and
`Pharmacokinetic (PK) Study of the Multitargeted
`Antifol (MTA) LY231514 with Folic Acid, Proc.
`Am. Soc’y Clinical Oncology, 17: Abstract 866
`(1998)
`
`12/14/2015
`
`Exhibit
`1015
`
`L. Hammond, et al., A phase I and pharmacokinetic
`(PK) study of the multitargeted antifolate (MTA,
`LY231514) with folic acid (FA), Annals Oncology, 9:
`129, Abstract 620P (1998)
`
`12/14/2015
`
`Exhibit
`1016
`
`C. Niyikiza, et al., LY231514 (MTA): Relationship of
`vitamin metabolite profile to toxicity, Proc. Am.
`Ass’n Cancer Res., 17: 558a, Abstract 2139 (1998)
`
`12/14/2015
`
`
`
`3
`
`

`
`Description
`
`Case IPR2016-00318
`Patent 7,772,209
`Filing Date
`
`12/14/2015
`
`12/14/2015
`
`12/14/2015
`
`12/14/2015
`
`12/14/2015
`
`12/14/2015
`
`12/14/2015
`
`12/14/2015
`
`Exhibit
`No.
`
`Exhibit
`1017
`
`Exhibit
`1018
`
`Exhibit
`1019
`
`Exhibit
`1020
`
`Exhibit
`1021
`
`Exhibit
`1022
`
`R. Thödtmann, et al., Preliminary Results of a Phase
`I Study with MTA (LY231415) in Combination with
`Cisplatin in Patients with Solid Tumors, Seminars
`Oncology, 26 (2, Suppl. 6): 89-93 (1999)
`
`U.S. Patent No. 5,563,126
`
`Ernest Beutler & James K. Weick, Blood and
`Neoplastic Disorders, in Current Clinical Practice
`(Messerli, ed., 1987), Ch. 1: 291-302
`
`Lars Brattström, Vitamins as Homocysteine-
`Lowering Agents, J. Nutrition, 126: 1276S-1280S
`(1996)
`
`Chuan Shih, et al., LY231514, a Pyrrolo[2,3-
`d]pyrimidine-based Antifolate That Inhibits Multiple
`Folate-requiring Enzymes, Cancer Res., 57, 1116-
`1123 (1997)
`
`G. Robbin Westerhof, et al., Carrier- and Receptor-
`Mediated Transport of Folate Antagonists Targeting
`Folate-Dependent Enzymes: Correlates of
`Molecular-Structure and Biological Activity, Am.
`Soc’y Pharmacology Experimental Therapeutics, 48:
`459-471 (1995)
`
`Exhibit
`1023
`
`F. G. Arsenyan, et al., Influence of Methylcobalamin
`on the Antineoplastic Activity of Methotrexate,
`Pharmaceutical Chemistry J., 12(10): 1299-1303
`(1978)
`
`Exhibit
`1024
`
`File History of U.S. Patent Application
`No. 11/288,807, Abandoned
`
`
`
`4
`
`

`
`Exhibit
`No.
`
`Exhibit
`1025
`
`Exhibit
`1026
`
`Exhibit
`1027
`
`Exhibit
`1028
`
`Exhibit
`1029
`
`Exhibit
`1030
`
`Exhibit
`1031
`
`Description
`
`Case IPR2016-00318
`Patent 7,772,209
`Filing Date
`
`U.S. Food & Drug Administration, Approved Drug
`Products with Therapeutic Equivalents Evaluations
`(30th ed. 2010)
`
`Z.P. Sofyina, et al., Possibility to Increase the
`Antitumor Effect of Folic Acid Antagonist with the
`Help of Methylcobalamine Analogs, Sci. Center
`Oncology 1:72-78 (1979)
`
`Victor Herbert, The Role of Vitamin B12 and Folate
`in Carcinogenesis, Advances Experimental Med.
`Biology, 206: 293-311 (1986)
`
`Glenn Tisman, et al., Overcoming Colon Cancer
`Resistance to Hepatic Artery Infusional 5FUdR
`Chemotherapy with Folinic Acid, Clinical Res.,
`33(2): 459A (1985)
`
`J.D. Kinloch, Maintenance Treatment of Pernicious
`Anaemia by Massive Parenteral Doses of Vitamin
`B12 at Intervals of Twelve Weeks, Brit. Med. J., 1:99-
`100 (1960)
`
`D. Wray, et al., Recurrent Aphthae: Treatment with
`Vitamin B12, Folic Acid, and Iron, Brit. Med. J.,
`2:490-93 (1975)
`
`J. Tamura, et al., Immunomodulation by Vitamin
`B12: Augmentation of CD8+ T Lymphocytes and
`Natural Killer (NK) Cell Activity in Vitamin B12-
`Deficient Patients by Methyl-B12 Treatment, Clin.
`Experimental Immunology, 116:28-32 (1999)
`
`12/14/2015
`
`12/14/2015
`
`12/14/2015
`
`12/14/2015
`
`12/14/2015
`
`12/14/2015
`
`12/14/2015
`
`Exhibit
`1032
`
`Carrasco et al., Acute Megaloblastic Anemia:
`Homocysteine Levels Are Useful for Diagnosis and
`Follow-Up, Haematologica, 84: 767- 768 (1999)
`
`12/14/2015
`
`
`
`5
`
`

`
`Exhibit
`No.
`
`Exhibit
`1033
`
`Exhibit
`1034
`
`Exhibit
`1035
`
`Exhibit
`1036
`
`Exhibit
`1037
`
`Exhibit
`1038
`
`Exhibit
`1039
`
`Exhibit
`1040
`
`Exhibit
`1041
`
`Description
`
`Case IPR2016-00318
`Patent 7,772,209
`Filing Date
`
`European Patent Application No. 0 595 005
`
`12/14/2015
`
`U.S. Patent No. 5,344,932
`
`Amended Joint Claim Construction Statement in Eli
`Lilly & Co. v. Teva Parenteral Medicines, Inc. et al.,
`No. 1:10-cv-1376 (S.D. Ind.), filed April 19, 2012
`(Dkt. 110)
`
`Excerpts from transcript of the trial on invalidity
`held between August 19 and August 29, 2013 in Eli
`Lilly & Co. v. Teva Parenteral Medicines, Inc., Case
`No. 1:10-cv-1376 (S.D. Ind.)
`
`E. Bajetta et al., Phase II study of pemetrexed
`disodium (Alimta®) administered with oral folic
`acid in patients with advanced gastric cancer,
`Annals of Oncology 14:1543-48 (2003).
`
`12/14/2015
`
`12/14/2015
`
`12/14/2015
`
`12/14/2015
`
`Letter dated February 4, 2004 from Robert Temple to
`John Worzalla concerning NDA 21-462
`
`12/14/2015
`
`Johan B. Ubbink et al., Vitamin Requirements for the
`Treatment of Hyperhomocysteinemia in Humans, J.
`Nutrition 124:1927-1933 (1994)
`
`12/14/2015
`
`Anja Brönstrup et al., Effects of folic acid and
`combinations of folic acid on plasma homocysteine
`concentrations in healthy, young women, Am. J.
`Clin. Nutr. 1998:68:1104-10 (1998)
`
`J. B. Ubbink, The role of vitamins in the
`pathogenesis and treatment of
`hyperhomocyst(e)inaemia, J. Inherited Metabolic
`Disease, 20:316-25 (1997)
`
`12/14/2015
`
`12/14/2015
`
`
`
`6
`
`

`
`Exhibit
`No.
`
`Exhibit
`1042
`
`Exhibit
`1043
`
`Description
`
`Case IPR2016-00318
`Patent 7,772,209
`Filing Date
`
`S. Sörenson et al., A systematic overview of
`chemotherapy effects in non-small cell lung cancer,
`Acta Oncologica 40(2-3):327-29 (2001)
`
`R. Thödtmann et al., Phase I study of different
`sequences of MTA (LY231514) in combination with
`cisplatin in patients with solid tumours, Annals
`Oncology, 9: 129, 618P (Abstract) (1998)
`
`12/14/2015
`
`12/14/2015
`
`Exhibit
`1044
`
`Complaint filed in Eli Lilly & Co. v. Teva Parenteral
`Medicines, Inc., No. 1:08-cv-335 (D. Del.) on June 5,
`2008
`
`12/14/2015
`
`Exhibit
`1045
`
`Calvert, MTA: Summary and Conclusions, Seminars
`in Oncology, 26 (2, Suppl. 6): 105-08 (1999)
`
`12/14/2015
`
`Exhibit
`1046
`
`Center for Drug Evaluation and Research, Product
`Development under the Animal Rule: Guidance for
`the Industry (October 2015)
`
`Exhibit
`1047
`
`A.H. Calvert & J.M. Walling, Clinical Studies with
`MTA, British J. Cancer (1998) 78 (Suppl. 3): 35-40
`
`Exhibit
`1048
`
`Exhibit
`1049
`
`Exhibit
`1050
`
`Center for Drug Evaluation and Research, Guidance
`for Industry: Single Dose Acute Toxicity Testing for
`Pharmaceuticals (August 1996)
`
`Center for Drug Evaluation and Research, E6 Good
`Clinical Practice: Consolidated Guidance (April
`1996)
`
`Robert H. Allen et al., Diagnosis of Cobalamin
`Deficiency I: Usefulness of Serum Methylmalonic
`Acid and Total Homocysteine Concentrations, Am. J.
`Hematology 34:90-98 (1990)
`
`12/14/2015
`
`12/14/2015
`
`12/14/2015
`
`12/14/2015
`
`12/14/2015
`
`Exhibit
`1051
`
`Eli Lilly & Company, Alimta® Labeling (Revised
`Sept. 2013)
`
`12/14/2015
`
`
`
`7
`
`

`
`Description
`
`Case IPR2016-00318
`Patent 7,772,209
`Filing Date
`
`Exhibit
`No.
`
`Exhibit
`1052
`
`Rusthoven et al., Multitargeted Antifolate LY231514
`as First-Line Chemotherapy for Patients with
`Advanced Non-Small-Cell Lung Cancer: A Phase II
`Study, J. Clin. Oncology, 17 (4) 1194-99 (April
`1999)
`
`Exhibit
`1053
`
`Return of Service, Eli Lilly & Co. v. Sandoz Inc.,
`Case No. 1:14-cv-2008 (S.D. Ind. Dec. 29, 2014)
`
`Exhibit
`1054
`
`Exhibit
`1055
`
`Exhibit
`1056
`
`Exhibit
`1057
`
`Exhibit
`1058
`
`FDA, Electronic Orange Book: Approved Drug
`Products and Therapeutic Equivalence Evaluations
`Entry for Alimta®, available at
`http://www.accessdata.fda.gov/scripts/cder/ob/docs/
`patexclnew.cfm?Appl_No=021462&Product_No=00
`1&table1=OB_Rx (last accessed Dec. 14, 2015)
`
`Declaration of Laura Lydigsen in support of
`Petitioner’s Motion to Admit Pro Hac Vice Laura A.
`Lydigsen as Backup Counsel
`
`Z.P. Sofyina, et al., Possibility to Increase the
`Antitumor Effect of Folic Acid Antagonist with the
`Help of Methylcobalamine Analogs, Sci. Center
`Oncology 1:72-78 (1979)
`
`Victor Herbert, The Role of Vitamin B12 and Folate
`in Carcinogenesis, Advances Experimental Med.
`Biology, 206: 293-311 (1986)
`
`J. Tamura, et al., Immunomodulation by Vitamin
`B12: Augmentation of CD8+ T Lymphocytes and
`Natural Killer (NK) Cell Activity in Vitamin B12-
`Deficient Patients by Methyl-B12 Treatment, Clin.
`Experimental Immunology, 116:28-32 (1999)
`
`12/14/2015
`
`12/14/2015
`
`12/14/2015
`
`2/25/2016
`
`Not filed
`
`Not filed
`
`Not filed
`
`Exhibit
`1059
`
`Cover page for Certified electronic copy of File
`History for U.S. Patent No. 7,772,209
`
`Not filed
`
`
`
`8
`
`

`
`Description
`
`Declaration of Laura A. Lydigsen
`
`Case IPR2016-00318
`Patent 7,772,209
`Filing Date
`
`Not filed
`
`Not filed
`
`Supplemental Declaration of Ron D. Schiff, M.D.,
`Ph. D.
`
`Transcript of October 31, 2016 Telephone Hearing
`
`11/9/2016
`
`9
`
`Exhibit
`No.
`
`Exhibit
`1060
`
`Exhibit
`1061
`
`Exhibit
`1062
`
`
`
`
`
`

`
`CERTIFICATE OF SERVICE
`
`Case IPR2016-00318
`Patent 7,772,209
`
`I hereby certify that true and correct copies of the foregoing document were
`served on November 9, 2016 via email to the following individuals at the email
`addresses below.
`
`Dov P. Grossman (Reg. No. 72,525)
`Williams & Connolly LLP
`725 Twelfth St. NW
`Washington DC 20005
`Direct Phone: 202-434-5812
`Facsimile: 202-434-5029
`dgrossman@wc.com
`
`David M. Krinsky (Reg. No. 72,339)
`Williams & Connolly LLP
`725 Twelfth St. NW
`Washington DC 20005
`Direct Phone: 202-434-5338
`Facsimile: 202-480-8302
`dkrinsky@wc.com
`
`Adam L. Perlman
`Williams & Connolly LLP
`725 Twelfth St. NW
`Washington DC 20005
`Direct Phone: 202-434-5244
`aperlman@wc.com
`
`James P. Leeds (Reg. No. 35,241)
`Eli Lilly and Company
`Lilly Corporate Center
`Indianapolis, IN 46285
`Direct Phone: 317-276-1667
`Facsimile: 317-277-6534
`leeds_james@lilly.com
`
`John C. Demeter (Reg. No. 30,167)
`Eli Lilly and Company
`Lilly Corporate Center
`
`
`
`
`
`

`
`
`
`Dated: November 9, 2016
`
`
`
`
`
`
`Case IPR2016-00318
`Patent 7,772,209
`
`Indianapolis, IN 46285
`Direct Phone: 317-276-3785
`Facsimile: 317-276-3861
`demeter_john_c@lilly.com
`
`
`
`
`
`/s/ Ralph J. Gabric
`Ralph J. Gabric (Reg. No. 34,167)
`Laura L. Lydigsen
`Bryan T. Richardson, Ph.D. (Reg. No.
`70,572)
`Joshua H. James (Reg. No. 72,568)
`Brinks Gilson & Lione
`NBC Tower – Suite 3600
`455 N. Cityfront Plaza Dr.
`Chicago, Illinois 60611

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket